Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.Olotu, A. Moris, P. Mwacharo, J. Vekemans, J. Kimani, D. Janssens, M. Kai, O. Jongert, E. Lievens, M. Leach, A. Villafana, T. Savarese, B. Marsh, K. Cohen, J. Bejon, P.
PLoS One, (2011). 6:e25786

Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites.Bejon, P. Turner, L. Lavstsen, T. Cham, G. Olotu, A. Drakeley, C. J. Lievens, M. Vekemans, J. Savarese, B. Lusingu, J. von Seidlein, L. Bull, P. C. Marsh, K. Theander, T. G.
PLoS One, (2011). 6:e21711

Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children.Liljander, A. Bejon, P. Mwacharo, J. Kai, O. Ogada, E. Peshu, N. Marsh, K. Farnert, A.
PLoS One, (2011). 6:e16940

Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya.Olotu, A. Fegan, G. Williams, T. N. Sasi, P. Ogada, E. Bauni, E. Wambua, J. Marsh, K. Borrmann, S. Bejon, P.
PLoS One, (2010). 5:e15569

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.Lusingu, J. Olotu, A. Leach, A. Lievens, M. Vekemans, J. Olivier, A. Benns, S. Olomi, R. Msham, S. Lang, T. Gould, J. Hallez, K. Guerra, Y. Njuguna, P. Awuondo, K. O. Malabeja, A. Abdul, O. Gesase, S. Dekker, D. Malle, L. Ismael, S. Mturi, N. Drakeley, C. J. Savarese, B. Villafana, T. Ballou, W. R. Cohen, J. Riley, E. M. Lemnge, M. M. Marsh, K. Bejon, P. von Seidlein, L.
PLoS One, (2010). 5:e14090

Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine.Mwacharo, J. Dunachie, S. J. Kai, O. Hill, A. V. Bejon, P. Fletcher, H. A.
PLoS One, (2009). 4:e8434

Interactions between age and ITN use determine the risk of febrile malaria in children.Bejon, P. Ogada, E. Peshu, N. Marsh, K.
PLoS One, (2009). 4:e8321

Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans.Todryk, S. M. Bejon, P. Mwangi, T. Plebanski, M. Urban, B. Marsh, K. Hill, A. V. Flanagan, K. L.
PLoS One, (2008). 3:e2027

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Bejon, P. Ogada, E. Mwangi, T. Milligan, P. Lang, T. Fegan, G. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
PLoS One, (2007). 2:e707